Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY to make an "Oral Presentation" on Bracelet-1 at ASCO

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Apr 26, 2023 1:54pm

118 Views

Post# 35415062

RE:RE:ONCY to make an "Oral Presentation" on Bracelet-1 at ASCO

To be clearer, by pharma collaboration I meant the following. For example, Roche and Oncolytics apply for one AA, and Merck/ Pfizer and Oncolytics apply for a second AA. I know I am rushing the fences, but this is exciting and does not even consider CRC et al.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023